News articles about Tekla Healthcare Investors (NYSE:HQH) have trended positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tekla Healthcare Investors earned a news impact score of 0.30 on Accern’s scale. Accern also gave news stories about the financial services provider an impact score of 43.5415347933107 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Tekla Healthcare Investors (NYSE HQH) traded up 0.92% on Friday, hitting $24.05. 221,502 shares of the stock traded hands. The stock has a 50-day moving average of $25.44 and a 200-day moving average of $24.54. Tekla Healthcare Investors has a 12-month low of $19.92 and a 12-month high of $27.35.

COPYRIGHT VIOLATION WARNING: “Tekla Healthcare Investors (HQH) Earns Daily Media Impact Rating of 0.30” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at

Tekla Healthcare Investors Company Profile

Tekla Healthcare Investors is a non-diversified closed-end healthcare fund. The Fund’s investment objective is to seek long-term capital appreciation by investing primarily in securities of healthcare companies. It seeks to provide regular distribution of realized capital gains. It may invest up to 20% of its net assets in securities of foreign issuers, located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded in foreign markets.

Receive News & Ratings for Tekla Healthcare Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tekla Healthcare Investors and related companies with Analyst Ratings Network's FREE daily email newsletter.